Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive

ACS Chem Biol. 2006 Jun 20;1(5):279-84. doi: 10.1021/cb600224w.

Abstract

Two recent papers attempt to solve both the tumor selectivity and the in vivo tumor accumulation profiles seen with some Hsp90 inhibitors. They spotlight the higher affinity of ansamycins' hydroquinone over the quinone form for Hsp90 and further discuss its possible contribution to ansamycins' tumor selectivity.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / classification
  • Antineoplastic Agents / pharmacology*
  • HSP90 Heat-Shock Proteins / antagonists & inhibitors*
  • HSP90 Heat-Shock Proteins / physiology*
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism*
  • Neoplasms / pathology

Substances

  • Antineoplastic Agents
  • HSP90 Heat-Shock Proteins